Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice.
To evaluate the biochemical and molecular mechanisms leading to glomerulosclerosis and the variable development of atherosclerosis in patients with familial lecithin cholesterol acyl transferase (LCAT) deficiency, we generated LCAT knockout (KO) mice and cross-bred them with apolipoprotein (apo) E KO, low density lipoprotein receptor (LDLr) KO, and cholesteryl ester transfer protein transgenic mice. LCAT-KO mice had normochromic normocytic anemia with increased reticulocyte and target cell counts as well as decreased red blood cell osmotic fragility. A subset of LCAT-KO mice accumulated lipoprotein X and developed proteinuria and glomerulosclerosis characterized by mesangial cell proliferation, sclerosis, lipid accumulation, and deposition of electron dense material throughout the glomeruli. LCAT deficiency reduced the plasma high density lipoprotein (HDL) cholesterol (-70 to -94%) and non-HDL cholesterol (-48 to -85%) levels in control, apoE-KO, LDLr-KO, and cholesteryl ester transfer protein-Tg mice. Transcriptome and Western blot analysis demonstrated up-regulation of hepatic LDLr and apoE expression in LCAT-KO mice. Despite decreased HDL, aortic atherosclerosis was significantly reduced (-35% to -99%) in all mouse models with LCAT deficiency. Our studies indicate (i) that the plasma levels of apoB containing lipoproteins rather than HDL may determine the atherogenic risk of patients with hypoalphalipoproteinemia due to LCAT deficiency and (ii) a potential etiological role for lipoproteins X in the development of glomerulosclerosis in LCAT deficiency. The availability of LCAT-KO mice characterized by lipid, hematologic, and renal abnormalities similar to familial LCAT deficiency patients will permit future evaluation of LCAT gene transfer as a possible treatment for glomerulosclerosis in LCAT-deficient states.
Lambert
G
G
Molecular Disease Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA. gl68i@nih.gov
Sakai
N
N
Vaisman
B L
BL
Neufeld
E B
EB
Marteyn
B
B
Chan
C C
CC
Paigen
B
B
Lupia
E
E
Thomas
A
A
Striker
L J
LJ
Blanchette-Mackie
J
J
Csako
G
G
Brady
J N
JN
Costello
R
R
Striker
G E
GE
Remaley
A T
AT
Brewer
H B
HB
Santamarina-Fojo
S
S
D000818:Animals; D001161:Arteriosclerosis / Q000201:enzymology* / Q000503:physiopathology; D001483:Base Sequence; D017931:DNA Primers; D005923:Glomerulosclerosis, Focal Segmental / Q000201:enzymology* / Q000503:physiopathology; D007668:Kidney / Q000503:physiopathology; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008854:Microscopy, Electron; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000097:blood / Q000235:genetics / Q000502:physiology*; D012333:RNA, Messenger / Q000235:genetics
D017931:DNA Primers; D008055:Lipids; D008074:Lipoproteins; D012333:RNA, Messenger; D007862:Phosphatidylcholine-Sterol O-Acyltransferase